214 related articles for article (PubMed ID: 37935567)
1. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.
Lv K; Sun M; Fang H; Wang J; Lin C; Liu H; Zhang H; Li H; He H; Gu Y; Li R; Shao F; Xu J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935567
[TBL] [Abstract][Full Text] [Related]
2. Siglec-9
Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296
[TBL] [Abstract][Full Text] [Related]
3. Blocking siglec-10
Xiao N; Zhu X; Li K; Chen Y; Liu X; Xu B; Lei M; Xu J; Sun HC
Exp Hematol Oncol; 2021 Jun; 10(1):36. PubMed ID: 34112250
[TBL] [Abstract][Full Text] [Related]
4. Complement receptor C5aR1 blockade reprograms tumor-associated macrophages and synergizes with anti-PD-1 therapy in gastric cancer.
Zhang P; Gu Y; Wang J; Lv K; Lin C; Zhang H; Li H; He H; Li R; Liu H; Xu J
Int J Cancer; 2023 Jul; 153(1):224-237. PubMed ID: 36799619
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
[TBL] [Abstract][Full Text] [Related]
6. C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer.
Liu X; Lv K; Wang J; Lin C; Liu H; Zhang H; Li H; Gu Y; Li R; He H; Xu J
Br J Cancer; 2023 Sep; 129(4):721-732. PubMed ID: 37422529
[TBL] [Abstract][Full Text] [Related]
7. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
[TBL] [Abstract][Full Text] [Related]
8. Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer.
Cao Y; Yu K; Zhang Z; Gu Y; Gu Y; Li W; Zhang W; Shen Z; Xu J; Qin J
Clin Transl Med; 2024 Feb; 14(2):e1578. PubMed ID: 38356419
[TBL] [Abstract][Full Text] [Related]
9. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
10. Blockade of DC-SIGN
Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
[TBL] [Abstract][Full Text] [Related]
12. Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas.
Li B; Guo Y; Yi Y; Huang Z; Ren Y; Wang H; Yang L
J Transl Med; 2023 Sep; 21(1):599. PubMed ID: 37674198
[TBL] [Abstract][Full Text] [Related]
13. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
[TBL] [Abstract][Full Text] [Related]
14. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity.
Li Y; Shen Z; Chai Z; Zhan Y; Zhang Y; Liu Z; Liu Y; Li Z; Lin M; Zhang Z; Liu W; Guan S; Zhang J; Qian J; Ding Y; Li G; Fang Y; Deng H
Gut; 2023 Nov; 72(12):2307-2320. PubMed ID: 37507218
[TBL] [Abstract][Full Text] [Related]
15. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.
Haas Q; Markov N; Muerner L; Rubino V; Benjak A; Haubitz M; Baerlocher GM; Ng CKY; Münz C; Riether C; Ochsenbein AF; Simon HU; von Gunten S
Front Immunol; 2022; 13():996746. PubMed ID: 36211376
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer.
Xu Y; Zeng H; Jin K; Liu Z; Zhu Y; Xu L; Wang Z; Chang Y; Xu J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338085
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer.
Zhang H; Liu Z; Wen H; Guo Y; Xu F; Zhu Q; Yuan W; Luo R; Lu C; Liu R; Gu J; Ge D
Cancer Immunol Immunother; 2022 Oct; 71(10):2511-2522. PubMed ID: 35278107
[TBL] [Abstract][Full Text] [Related]
18. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.
Stanczak MA; Rodrigues Mantuano N; Kirchhammer N; Sanin DE; Jacob F; Coelho R; Everest-Dass AV; Wang J; Trefny MP; Monaco G; Bärenwaldt A; Gray MA; Petrone A; Kashyap AS; Glatz K; Kasenda B; Normington K; Broderick J; Peng L; Pearce OMT; Pearce EL; Bertozzi CR; Zippelius A; Läubli H
Sci Transl Med; 2022 Nov; 14(669):eabj1270. PubMed ID: 36322632
[TBL] [Abstract][Full Text] [Related]
19. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
20. Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma.
Chen Q; Chen B; Wang C; Hu L; Wu Q; Zhu Y; Zhang Q
Front Immunol; 2023; 14():1159085. PubMed ID: 37234161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]